Jazz Pharmaceuticals (JAZZ) is rallying after posting first-quarter 2026 results that topped expectations and showed broad-based commercial strength. The company reported total revenue of $1.1 billion, up 19% year over year, and delivered non-GAAP EPS of $6.34, helping drive a sharp move higher in the stock today.

The quarter’s headline growth was supported by continued momentum in core franchises, including Xywav net product sales of $408 million (+18% year over year) and Epidiolex revenues up 15% year over year. Jazz also generated $408 million in cash from operations in the quarter, reinforcing confidence in near-term execution and cash generation capacity.

Jazz reaffirmed its 2026 total revenue guidance range of $4.25 billion to $4.50 billion, which is helping reduce concerns about a post-earnings hangover and keeps attention on upcoming catalysts. The company highlighted regulatory progress for zanidatamab in first-line HER2+ gastroesophageal adenocarcinoma, noting Priority Review status and an August 25, 2026 PDUFA date, a timeline that investors are now treating as a major 2026 event.

Next focus points include continued patient adds and payer/physician dynamics in the sleep franchise, durability of Epidiolex growth, and traction from newer oncology offerings referenced in the quarterly update. Into the summer, investor attention is likely to intensify around regulatory milestones and any additional clinical or commercial updates tied to zanidatamab ahead of the late-August decision date.